

Axonal Damage Caused by Exposure of Axon Terminals to Amyloid Beta

D. Carrick¹, B. Campbell², H-F. Liang³, W-X. Shi⁴, and S-W. Sun⁵

¹Basic Science, School of Medicine, Loma Linda University, Loma Linda, CA, United States, ²Clinical Laboratory Science, School of Allied Health, Loma Linda University, Loma Linda, ³Biophysics and Bioengineering, Loma Linda University, ⁴Pharmaceutical Sciences and Basic Sciences, Schools of Pharmacy and Medicine, Loma Linda University, ⁵Biophysics and Bioengineering, Loma Linda University, Loma Linda, CA, United States



Introduction

Amyloid Beta (A β) is the principal component in amyloid plaques and has been implicated as the primary toxic factor in Alzheimer's disease pathogenesis (1). However, the mechanism of how A β to induce neurodegeneration is not clear. Given the fact that a large number of soluble A β are produced around synapses (2), despite of the synaptic vulnerability to A β , it has never been demonstrated whether a focal exposure of axonal terminals to A β may lead to a dying-back axonal degeneration. An experiment designed to allow the axonal terminal sites but not neuronal body (soma) to be exposed to A β would provide an answer to this question.

In this study, we address this issue on visual system, in which the optic nerve and optic tract are axons inside the brain, and the soma, the retinal ganglion cells (RGCs), sit in the eye. The A β injected into optic tract terminals would be less likely to affected RGC bodies directly. As such, only the axon but not the soma would be affected by A β after the brain injection of A β . Diffusion Tensor Imaging (DTI) and histology were performed to evaluate the optic tract degeneration after the A β injection.

Materials and Methods

Twelve female C57BL/6 mice at 12 weeks old were separated into two groups. For experimental group, A β peptides (4 n mole in 3 μ l) were injected into the right hemisphere dorsal lateral geniculate (LGd) area, which are the axonal terminals of optic tracts. In 1 and 3 months after A β injection, mice were anesthetized with a mixture of oxygen and isoflurane (Baxter Healthcare Corporation, IL, USA) for imaging. Spin-echo DTI were collected using a Bruker 4.7T BioSpec small animal MRI instrument with TR 3 s, TE 29 ms, diffusion gradient pair (Δ) = 20 ms, diffusion gradient duration (δ) = 3 ms, a six-direction diffusion scheme with b-values of 0 and 0.85 ms/ μ m², slice thickness 0.5 mm, field of view of 1.5 cm x 1.5 cm, and matrix 256 x 256. Using program written in Matlab (MathWorks, Natick, MA, USA), the axial diffusivity ($\lambda_{||}$), radial diffusivity (λ_{\perp}), relative anisotropy (RA), and trace of the diffusion tensor (Tr) were calculated. Regions of interest (ROI) were selected in optic nerves, optic tracts, corpus callosum, and external capsule. Data were presented as mean \pm standard deviation. Repeated measures analysis of variance (ANOVA) was carried out. P-values were considered to be statistically significant at $\alpha < 0.05$.



Results

Among the measured white matter tracts, only optic tracts and optic nerves showed A β effects. The ipsilateral optic tracts showed significant a 15% decrease of $\lambda_{||}$. In optic nerves, the only the contralateral but not the ipsilateral optic nerves showed abnormalities. The contralateral optic nerves appeared 10% decreases of Tr in 3 months after A β injection.

Discussion and Conclusions

This study demonstrated the axonal degeneration induced by the exposure of axonal terminal sites to the A β . After A β injection, the ipsilateral optic tracts appeared abnormal with a 15% decrease of $\lambda_{||}$. The significant 10% Tr decrease in contralateral optic nerves may relate to the ipsilateral optic tract degeneration as a result of A β injection. All brains were currently under the process for immunohistological examinations.

References (1) Yankner, B. A. et al. *Science* 245, 417-420, (1989). (2) Cirrito, J. R. et al.. *Neuron* 48, 913-922, (2005).

Acknowledgement: NIH-3R01NS054001-03S1.